|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tempero MA, Malafa MP, Al-Hawary M, Asbun
H, Bain A, Behrman SW, Betnson AB III, Binder E, Cardin DB, Cha C,
et al: Pancreatic adenocarcinoma, version 2. 2017. NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
15:1028–1061. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hiyoshi M, Nanashima A, Wada T,
Tsuchimochi Y, Hamada T, Yano K, Imamura N and Fujii Y: A
successful case of locally advanced pancreatic cancer undergoing
curative distal pancreatectomy with en bloc celiac axis resection
after combination chemotherapy of nab-paclitaxel with gemcitabine.
Clin J Gastroenterol. 10:551–557. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saito T, Ishido K, Kudo N, Kimura N,
Wakiya T, Nakayama Y and Hakamada K: Combination therapy with
gemcitabine and nab-paclitaxel for locally advanced unresectable
pancreatic cancer. Mol Clin Oncol. 6:963–967. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumors (8th edition).
Wiley-Blackwell; New York: 2017
|
|
7
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancy J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumors:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyazaki M, Itoh H, Kaiho T, Ambiru S,
Togawa A, Sasada K, Shiobara M, Shimizu Y, Yoshioka S, Yoshitome H,
et al: Portal vein reconstruction at the hepatic hilus using a left
renal vein graft. J Am Coll Surg. 180:497–498. 1995.PubMed/NCBI
|
|
9
|
Evans DB, Rich TA, Byrd DR, Cleary KR,
Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ and Ames FC:
Preoperative chemoradiation and pancreaticoduodenectomy for
adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bassi C, Marchegiani G, Dervenis C, Sarr
M, Hilal Abu M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink
MG, et al: The 2016 update of the International Study Group (ISGPS)
definition and grading of postoperative pancreatic fistula: 11
years after. Surgery. 161:584–591. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T,
Nakajima TE and Furuse J: Phase I/II study of nab-paclitaxel plus
gemcitabine for chemotherapy-naive Japanese patients with
metastatic pancreatic cancer. Cancer Chemother Pharmacol.
77:595–603. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Satoi S, Yamaue H, Kato K, Takahashi S,
Hirono S, Takeda S, Eguchi H, Sho M, Wada K, Shinchi H, et al: Role
of adjuvant surgery for patients with initially unresectable
pancreatic cancer with a long-term favorable response to
non-surgical anti-cancer treatments: Results of a project study for
pancreatic surgery by the Japanese Society of
Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci.
20:590–600. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ielpo B, Duran H, Diaz E, Fabra I, Caruso
R, Ferri V, Malavé L, Hidalgo M, Alvarez R, Plaza C, et al:
Preoperative treatment with gemcitabine plus nab-paclitaxel is a
safe and effective chemotherapy for pancreatic adenocarcinoma. Eur
J Surg Oncol. 42:1394–1400. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Conroy T, Desseifne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suker M, Beumer BR, Sadot E, Marhey L,
Faris JE, Mellon EA, EI-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ,
et al: FOLFIRINOX for locally advanced pancreatic caner: A
systematic review and patient-lebel meta-analysis. Lancet Oncol.
17:801–810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Boone BA, Steve J, Zenati MS, Hogg ME,
Singhi AD, Barlett DL, Zureikat AH, Bahary N and Zeh HJ III: Serum
CA 19-9 response to neoadjuvant therapy is associated with outcome
in pancreatic adenocarcinoma. Ann Surg Oncol. 21:4351–4358. 2014.
View Article : Google Scholar : PubMed/NCBI
|
